Bacillus anthracis protective antigen nucleic acid sequences

US8044189B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Stephen H. Leppla · Bethesda, US
• Yogendra Singh · Cupertino, US
• Kurt Klimpel · Gaithersburg, US
• Rachel Schneerson · Bethesda, US
• John B. Robbins · New York, US

Key dates

• Filing date: Jun 15, 2010
• Grant date: Oct 25, 2011
• Expiry date: Jun 15, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/53
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.